We live in a pandemic of chronic diseases, with an increasing number of pesticides, chemicals and food additions involved in the low health of Americans. Since 2019, there has been another playing factor as well: SARS-COV-2 has a significant increase in chronic health consequences, which are widely referred to as AS Long coffee.
Infection by the Covid-19 virus is a new variable depending on our nation’s health that can significantly increase the occurrence of dangerous conditions such as Nervous diseaseand heart attack and Stroke. Nearly 6 % of the two long long – at a cost of our economy It is estimated at 3.7 trillion dollars a year.
Contrary to what is often photographed in the media, long Covid is not a mystery. There is at least a direct cause that some people may remain sick “after Covid”: they still have the SARS-COV-2-or parts of the virus-in their bodies. For example, one team I found it Nearly two years after the injury, the long patients did not establish the virus from the intestine tissues. These persistent viral tanks seem to be Spike protein leakage – Part of the virus that gives Corona viruses the distinctive “crown” appearance – in blood circulation, and may lead brain inflammation and other organs, and increase health consequences such as My heart.
While early efforts are underway to help remove continuous viral tanks, an urgent need for clinical trials is well designed to help millions of suffering from a long return to normal life. To address this emergency, we have formed International consortium From scholars to accelerate research, including publication Modern road map for drug test It aims to purify the SARS -2 -2 continuous. Our proposal depends on the successful approach of the strategies of research and treatment of cancer used against other viral infections such as HIV and hepatitis; These dates offer lessons on experimenting design and drug candidates and how to develop continuous viral tank tests.
The most promising experiments may also be among the most complex experiments, as they may combine drugs that target the virus – such as antiviral drugs and unilateral antibodies – with treatments to stimulate immune cells. It may also be important to address other problems associated simultaneously associated with long Covid, such as immune dysfunction and microbium changes.
To add another variable to these complex experiences, we do not know after the duration of treatment that each type of medicine may need. For example, the current long clinical trials are tested from 5 to 15 days of antivirals such as Paxlovid. But continuous hepatitis virus treatment requires 8 to 12 weeks of antiviral treatment. In cats with catititis Cats – also caused by a fixed Coronavirus – 12 weeks of antiviral therapy required for effective treatment. Such an extensive approach may require accurate studies to test the integrity of possible long medications when giving it for longer periods of time.
All this will be a global multidisciplinary task. But the effort is worth it.
The question that is waving on the horizon now is: Who will pay the price of drug development and trials? Large pharmaceutical companies can conduct experiments, and they must. But small biotechnology companies do not have the same resources. Indeed, due to this restriction, many antibodies and unilateral antibodies with the ability to help long patients can help shelves instead of studying in patients who need more options.
Government and private financing should be solved by this by helping smaller companies conducting early stage experiments. These programs, which must be graceful and adaptive and constantly include the experience of patients in their design, is ideal for “high -risk, highly rewarding” agencies such as the Advanced Health Research Projects Agency, which is part of health and humanitarian services. So it was encouraging to hear Robert Kennedy Junior, who is now the Minister of Health and Humanitarian Services, Say during the last confirmation session It will work enthusiastically with Congress to direct long long funding towards clinical trials that are intense.
If general financing supports the development of any new long medication, the resulting data and treatments should be open source and available for public performance manufacturers, which will increase confidence in treatments and will benefit patients all over the world.
The world was in this position before, when it faced HIV in the late eighties and early 1990s. A combination of government and private financing has made many companies ready to participate in the development of medicines. There are now more than 25 accredited drugs from HIV infection. On developing these HIV treatments from a life-threatening infection to a chronic control-for those who have access to medicines. In some cases, public support forced pharmaceutical companies that are appropriate to work together to work together for the greatest good.
Lessons learned from the fight against SARS-COV-2 can help scientists in battles against other cases, because the long length is just one of many chronic front countries that start with infection. Others include a chronic or post -therapy Lyme disease, muscle encephalitis, and fatigue syndrome after the attack. Viral infection is also increasingly documented among the patients of Alzheimer’s and multiple sclerosis.
The urgency of the long length is an invitation to weapons for government and private financiers to help bring medications and protocols to the people they need. In the end, more acquired knowledge may benefit.
Emmy D.A microbiologist, the founder of the Polybio Research Foundation, a non -profit organization that supports research in the root motives of chronic diseases. Chan Soon-SOON-Shiong Family, led by the Times owner, Dr. Patrick Skkon Chiong, is an financier of Polybio research.